View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
September 17, 2018

Millendo Therapeutics starts Phase llb trial of nevanimibe for CAH

Millendo Therapeutics has begun a Phase llb clinical trial to investigate the efficacy and safety of nevanimibe for the treatment of patients with classic congenital adrenal hyperplasia (CAH).

Millendo Therapeutics has begun a Phase llb clinical trial to investigate the efficacy and safety of nevanimibe for the treatment of patients with classic congenital adrenal hyperplasia (CAH).

CAH is a rare inherited endocrine disease, which is the result of a genetic mutation preventing cortisol synthesis and is characterised by overgrowth of the adrenal glands, adrenal insufficiency, and other factors.

The new open-label, intra-subject, dose-escalation trial aims to include up to 24 adult CAH patients who are on the current standard of care, glucocorticoids.

During the course of the trial, patients will be treated with nevanimibe for 12 consecutive weeks starting with a dose of 1,000mg BID.

Depending on 17 hydroxyprogesterone (17-OHP) levels, the dose will be increased to 1,500mg BID or 2,000mg BID.

“Our Phase llb trial will explore longer durations of treatment and higher doses of nevanimibe with the objective of enabling more patients to achieve hormonal control.”

The trial’s primary objective is to evaluate the percentage of patients that achieve 17-OHP levels less than or equal to two times the upper limit of normal (ULN).

Its secondary objectives comprise evaluation of other adrenal hormones, including androgens.

Millendo Therapeutics president and CEO Julia Owens said: “We are encouraged by the positive Phase ll efficacy and safety results of nevanimibe that were presented at the Endocrine Society’s annual meeting in March, in which these data demonstrated reductions in key steroids and steroid precursors, including promising reductions in 17-OHP, a key measure of disease control.

“Our Phase llb trial will explore longer durations of treatment and higher doses of nevanimibe with the objective of enabling more patients to achieve hormonal control.”

Nevanimibe, formerly ATR-101, is an adrenal-selective inhibitor of acylCoA:cholesterol acyltransferase 1 (ACAT1) enzyme that catalyses the transformation of free cholesterol into cholesterol ester.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU